Jean-Michel Dogné on The Aspirin Dosing after Trump’s Announcement
Jean-Michel Dogné, Full Professor and Dean of the Faculty of Medicine at Namur University, shared on LinkedIn:
”Approximations and blatant errors…
From the great Trump
- The aspirin (ASA) does not “thin” or “liquefy” the blood!
Acetylsalicylic acid has no effect on blood viscosity.
Its mechanism of action is well known:
- inhibition of platelet aggregation,
- by irreversibly blocking platelet COX-1,
- leading to a decrease in thromboxane A₂ synthesis.
Talking about “thick blood” or “thin blood” is therefore a misleading simplification with no pathophysiological basis.
2. In cardiovascular (secondary) prevention, we are not talking about high doses!
The recommendations are very clear:
- Low-dose ASA, generally 75 to 100 mg per day.
Furthermore, in patients aged ≥ 70 with no history of cardiovascular disease, data show no net benefit from low-dose ASA and a significant increase in major bleeding!
In practice, the recommendations therefore advise against initiating ASA for primary prevention in these patients.”
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25